| Project/Area Number |
26462488
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
味村 和哉 大阪大学, 医学系研究科, 助教 (50437422)
冨松 拓治 大阪大学, 医学系研究科, 講師 (30346209)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 妊娠高血圧症候群 / sFlt1 / sEng / vardenafil / 骨髄細胞移植 / 免疫寛容 / 妊娠性高血圧症候群 / 既存薬ライブラリー / soluble Endoglin / placental growth factor / HUVEC |
|---|
| Outline of Final Research Achievements |
Preeclampsia, a pregnancy disorder characterized by hypertension in association with proteinuria, is detected as a complication in 3-5% of all pregnancies 1 and is the leading cause of maternal and perinatal morbidity and mortality worldwide. Currently, preeclampsia cannot be prevented, and termination of pregnancy remains the only approach to treat preeclampsia.
By drug repositioning process through screening a library of approved drugs, we identified vardenafil which induced PlGF production from HUVEC. Although we showed that vardenafil induced PlGF production from BeWo cell, we could not show clear dose-response relation.
Further work is needed to determine whether vardenafil can be used for preeclampsia therapeutics before testing it in humans.
|
